Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line

BioImpacts

Volumn 3, Issue 2, 2013, Pages 67-74

  Ebrahimnezhad, Zohreh ^a,b   Zarghami, Nosratollah ^a,b   Keyhani, Manoutchehr ^c   Amirsaadat, Soumaye ^a   Akbarzadeh, Abolfazl ^a   Rahmati, Mohammad ^b   Taheri, Zohreh Mohammad ^d   Nejati Koshki, Kazem ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; MTT Assay; PLGA PEG Fe3O4; Real Time PCR; Silibinin; Telomerase

Indexed keywords

IRON OXIDE; MACROGOL; MESSENGER RNA; POLYGLACTIN; SILIBININ; TELOMERASE REVERSE TRANSCRIPTASE; TETRAMETHOXYSILANE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; BREAST CANCER; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; ENCAPSULATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROPHOBICITY; INFRARED SPECTROSCOPY; MORPHOLOGY; NANOEMULSION; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOLUBILITY;

EID: 84881534495     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2013.005     Document Type: Article

References (22)

1. Yassaee VR, Zeinali S, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, et al. Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res 2002;4:R6.
2. Tian N, Gaines WJ, Benjamin ZF. Female breast cancer mortality clusters within racial groups in the United States. Health Place 2010;16:209-18.
3. Lingner J, Cooper JP, Cech TR. Telomerase and DNA end replication: No longer a lagging strand problem? Science 1995;269:1533-4.
4. Kim NW. Clinical implications of Telomerase In cancer. Eur J Cancer 1997; 33:781-6.
5. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and Telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996;16:53-65.
6. Noh EM, Yi MS, Youn HJ, Lee BK, Lee YR, Han JH, et al. Silibinin enhances ultraviolet b-Induced apoptosis in MCF-7 human breast cancer cells. J Breast Cancer 2011;14: 8-13.
7. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: Comparison with silymarin. Cancer Lett 1999;147: 77-84.
8. Rahis-Uddin IA, Salim K, Rather MA, Wani WA, Haque A. Advances in nanodrugs for cancer chemotherapy. Current Cancer Drug Targets 2011;11:135-46.
9. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001;70:63-70.
10. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002;79:123-35.
11. Akbarzadeh A, Mikaeili H, Zarghami N, Rahmati M, Barkhordari A, Davaran A. Preparation and in vitro evaluation of doxorubicinloaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. International Journal of Nanomedicine 2012;7:511-26.
12. Kedar E, Palqi O, Golod G, Babai I, Barenholz Y. Delivery of cytokines by liposomes. III. Iposomeencapsulated GMCSF and TNF-a show improved pharmacokinetics and biological activety and reduced toxicity in mice. J Immunother 1997;20:180-193.
13. Yasui K, Nakamura Y. Positively charged liposomes containing tumor necrosis factor in solid tumors. Biol Pharm Bull 2000;23: 318-22.
14. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C loaded PLA nanoparticles. J Control Release 1999;60:179-88.
15. Dilnawaz F, Singh A, Mohanty A, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010;31:3694-706.
16. Kazemi-Lomedasht F, Zaraghami N, Fekri-aval S, Monfaredan A. ß-Cyclodextrin-curcumin complex inhibit telomerase gene expression in T47-D breast cancer cell line. African Journal of Biotechnology 2011;10:19481-8.
17. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AGA, Taylor DC, et al. Surface modification of poly(lac-tide-co-glycolide) nanoparticles by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 1994; 11:1800-8.
18. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Re 2006;85:220-5.
19. Raina K, Agarval R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: Efficacy and mechanisms. Acta Pharmacol Sin 2007;28:1466-75.
20. Kim S, Kim SH, Hur SM, Lee SK, Kim WW, Kim JS, et al. Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. J Ethnopharmacol 2009;126:252-7.
21. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of Telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 2004;171:1934-8.
22. Kennedy S, Geradts J, Bydlon T, Brown JQ, Gallagher J, Junker M, et al. Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast. Breast Cancer Res 2010;12:R91.